Correction to: Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients

Correction to: Clinical and Experimental Nephrology https://doi.org/10.1007/s10157-022-02188-y

In the original publication, the author has found errors as below:

• 1. The co-author Masayoshi Koinuma was inadvertently missed to include in the submitted manuscript. However, the co-author Masayoshi Koinuma has been updated in the online version.

• 2. The Fig. 1A and Fig. 1B are interchanged and scale (vertical axis) in Fig. 1c (25,000) is different with Fig. 1A, 1B and 1D (these are 60,000)-the scale of Fig. 1C has changed to 60,000. The corrected figures have been provided below (Fig. 1).

The original article has been corrected.

Fig. 1

SARS-CoV-2 antibody titer in HD and control group after full vaccination. The antibody titers were significantly lower in the HD group (n = 104) than in the healthy control group (n = 35) after full vaccination (control: 12,722.2 vs HD: 3848.8 AU/mL, p < 0.001) (A). When we conducted age-matched analysis (control: 8193.3 vs HD: 4295.8 AU/mL, p = 0.005) (B) and sex-matched analysis (only males; control: 9998.0 vs HD: 3650.2 AU/mL, p < 0.001 (C), only females; control: 13,285.8 vs HD: 4193.8 AU/mL, p < 0.001 (D)), the antibody titers were still significantly lower in HD group in every analysis. HD hemodialysis